Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Planta Med ; 83(17): 1351-1360, 2017 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-28561204

RESUMEN

(S)-Allyl-l-cysteine is the major bioactive compound in garlic. (S)-Allyl-l-cysteine is metabolized to (S)-allyl-l-cysteine sulfoxide, N-acetyl-(S)-allyl-l-cysteine, and N-acetyl-(S)-allyl-l-cysteine sulfoxide after oral administration. An accurate LC-MS/MS method was developed and validated for the simultaneous quantification of (S)-allyl-l-cysteine and its metabolites in rat plasma, and the feasibility of using it in pharmacokinetic studies was tested. The analytes were quantified by multiple reaction monitoring using an atmospheric pressure ionization mass spectrometer. Because significant quantitative interference was observed between (S)-allyl-l-cysteine and N-acetyl-(S)-allyl-l-cysteine as a result of the decomposition of N-acetyl-(S)-allyl-l-cysteine at the detector source, chromatographic separation was required to discriminate (S)-allyl-l-cysteine and its metabolites on a reversed-phase C18 analytical column with a gradient mobile phase consisting of 0.1% formic acid and acetonitrile. The calibration curves of (S)-allyl-l-cysteine, (S)-allyl-l-cysteine sulfoxide, N-acetyl-(S)-allyl-l-cysteine, and N-acetyl-(S)-allyl-l-cysteine sulfoxide were linear over each concentration range, and the lower limits of quantification were 0.1 µg/mL [(S)-allyl-l-cysteine and N-acetyl-(S)-allyl-l-cysteine] and 0.25 µg/mL [(S)-allyl-l-cysteine sulfoxide and N-acetyl-(S)-allyl-l-cysteine sulfoxide]. Acceptable intraday and inter-day precisions and accuracies were obtained at three concentration levels. The method satisfied the regulatory requirements for matrix effects, recovery, and stability. The validated LC-MS/MS method was successfully used to determine the concentration of (S)-allyl-l-cysteine and its metabolites in rat plasma samples after the administration of (S)-allyl-l-cysteine or aged garlic extract.


Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Cisteína/análogos & derivados , Ajo/química , Espectrometría de Masas/métodos , Extractos Vegetales/metabolismo , Administración Oral , Animales , Cisteína/administración & dosificación , Cisteína/química , Cisteína/metabolismo , Cisteína/farmacocinética , Masculino , Estructura Molecular , Extractos Vegetales/administración & dosificación , Extractos Vegetales/química , Extractos Vegetales/farmacocinética , Ratas , Ratas Sprague-Dawley
2.
J Pharm Sci ; 106(4): 961-967, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-27964938

RESUMEN

In this study, we evaluated the effect of coadministered metformin on the biliary excretion and liver concentration of atorvastatin. To investigate the inhibitory effect of metformin on biliary efflux transporters, the transport of atorvastatin in MDCKII-MDR1, BCRP, and MRP2 was evaluated. The effects of metformin on the steady state liver concentration and biliary excretion of atorvastatin and 2-hydroxyatorvastatin were evaluated in SDR and Mrp2-deficient EHBR. Metformin did not inhibit the transport of atorvastatin via BCRP and MDR1. However, metformin significantly inhibited the transport of atorvastatin and 2-hydroxyatorvastatin via MRP2 (apparent IC50 = 12 and 2 µM). Coadministered metformin significantly increased the Kp,liver and Cliver (1.7- and 1.6-fold) and decreased the biliary clearance of atorvastatin (2.7-fold) in SDR, but it did not affect the plasma concentration and total clearance of atorvastatin. Similar effects by metformin were observed for 2-hydroxyatorvastatin. In addition, coadministered metformin did not have any effect in EHBR. Therefore, coadministered metformin increases the liver concentration of atorvastatin via inhibition of the Mrp2 in rats, without affecting the plasma concentration. This "silent interaction" by metformin in atorvastatin and metformin combination therapy may be related to the unnoticeable pharmacological synergism or unpredicted side effects of atorvastatin in the liver.


Asunto(s)
Atorvastatina/metabolismo , Hígado/metabolismo , Metformina/metabolismo , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/antagonistas & inhibidores , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/metabolismo , Animales , Atorvastatina/administración & dosificación , Perros , Relación Dosis-Respuesta a Droga , Sinergismo Farmacológico , Hígado/efectos de los fármacos , Células de Riñón Canino Madin Darby , Masculino , Metformina/administración & dosificación , Proteína 2 Asociada a Resistencia a Múltiples Medicamentos , Ratas , Ratas Sprague-Dawley
3.
Phytochem Anal ; 25(4): 314-30, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24375623

RESUMEN

INTRODUCTION: Natural products have been used traditionally for the treatment and prevention of diseases for thousands of years and are nowadays consumed as dietary supplements and herbal medicine. To ensure the safe and effective use of these herbal products, information about bioavailability of active compounds in plasma or target tissues should be provided via validated analytical methods combined with appropriate sampling methods. OBJECTIVE: To provide comprehensive and abridged information about sample preparation methods for the quantification of phytochemicals in biological samples using liquid chromatography analysis. METHODS: Sample pre-treatment procedures used in analytical methods for in vivo pharmacokinetic studies of natural compounds or herbal medicines were reviewed. These were categorised according to the biological matrices (plasma, bile, urine, faeces and tissues) and sample clean-up processes (protein precipitation, liquid-liquid extraction and solid-phase extraction). RESULTS: Although various kinds of sample pre-treatment methods have been developed, liquid-liquid extraction is still widely used and solid-phase extraction is becoming increasingly popular because of its efficiency for extensive clean up of complex matrix samples. However, protein precipitation is still favoured due to its simplicity. CONCLUSION: Sample treatment for phytochemical analysis in biological fluids is an indispensable and critical step to obtain high quality results. This step could dominate the overall analytical process because both the duration of the process as well as the reliability of the data depend in large part on its efficiency. Thus, special attention should be given to the choice of a proper sample treatment method that targets analytes and their biomatrix.


Asunto(s)
Líquidos Corporales/química , Cromatografía Liquida/métodos , Fitoquímicos/análisis , Fitoquímicos/sangre , Fitoquímicos/orina , Extracción en Fase Sólida
4.
Biol Pharm Bull ; 35(5): 777-80, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22687416

RESUMEN

Curcumin has a wide spectrum of pharmacological activities, including antioxidant, anti-inflammatory, antimicrobial, and anticancer properties. Recently, its potential as effective chemoprevention against cholangiocarcinoma, a highly malignant tumor of the bile duct with limited therapeutic options, was reported. The purpose of the present study was to investigate the contribution of multidrug resistance-associated protein 2 (Mrp2) to the biliary excretion of curcumin using Sprague-Dawley rats (SDR) and Eisai hyperbilirubinemic rats (EHBR). After intravenous administration of curcumin with a loading dose of 4.5 mg/kg, followed by a constant infusion of 18 mg/kg/h to the SDR and EHBR, the pharmacokinetic parameters of curcumin were estimated. In EHBR, the total area under the bile concentration-time curve from 0 to 80 min following curcumin administration was dramatically decreased (0.094%) compared to that in SDR. In addition, the plasma-to-bile and liver-to-bile clearances were both significantly decreased compared to SDR. These results provide the first evidence that Mrp2 mediates the biliary excretion of curcumin and thus may be a major factor in the control of exposure of curcumin to the bile duct. This study may be helpful to the potential use of curcumin as a treatment for bile duct cancer, and to understanding the genetic polymorphism of Mrp2 for clinical trials of curcumin.


Asunto(s)
Neoplasias de los Conductos Biliares , Bilis/metabolismo , Sistema Biliar/metabolismo , Colangiocarcinoma , Curcumina/farmacocinética , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/metabolismo , Extractos Vegetales/farmacocinética , Animales , Neoplasias de los Conductos Biliares/tratamiento farmacológico , Neoplasias de los Conductos Biliares/metabolismo , Conductos Biliares Intrahepáticos , Colangiocarcinoma/tratamiento farmacológico , Colangiocarcinoma/metabolismo , Curcuma/química , Curcumina/administración & dosificación , Curcumina/uso terapéutico , Hiperbilirrubinemia/metabolismo , Hígado/metabolismo , Masculino , Proteína 2 Asociada a Resistencia a Múltiples Medicamentos , Fitoterapia , Extractos Vegetales/administración & dosificación , Extractos Vegetales/uso terapéutico , Plasma/metabolismo , Polimorfismo Genético , Ratas , Ratas Sprague-Dawley
5.
Planta Med ; 78(9): 909-13, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22573368

RESUMEN

Decursin is considered the major bioactive compound of Angelica gigas roots, a popular Oriental herb and dietary supplement. In this study, the pharmacokinetics of decursin and its active metabolite, decursinol, were evaluated after the administration of decursin in rats. The plasma concentration of decursin decreased rapidly, with an initial half-life of 0.05 h. It was not detectable at 1 h after intravenous administration at an area under the plasma concentration-time curve of 1.20 µg · mL-1·h, whereas the concentration of decursinol increased rapidly reaching a maximum concentration of 2.48 µg · mL-1 at the time to maximum plasma concentration of 0.25 h and an area under the plasma concentration-time curve of 5.23 µg · mL-1·h. Interestingly, after oral administration of decursin, only decursinol was present in plasma, suggesting an extensive hepatic first-pass metabolism of decursin. The extremely low bioavailability of decursin after its administration via the hepatic portal vein (the fraction of dose escaping first-pass elimination in the liver, FH = 0.11) is indicative of extensive hepatic first-pass metabolism of decursin, which was confirmed by a tissue distribution study. These findings suggest that decursin is not directly associated with the bioactivity of A. gigas and that it may work as a type of natural prodrug of decursinol.


Asunto(s)
Angelica/química , Benzopiranos/farmacocinética , Butiratos/farmacocinética , Administración Oral , Animales , Benzopiranos/administración & dosificación , Benzopiranos/sangre , Disponibilidad Biológica , Butiratos/administración & dosificación , Butiratos/sangre , Semivida , Masculino , Vena Porta , Ratas , Ratas Sprague-Dawley , Distribución Tisular
6.
Int J Pharm ; 410(1-2): 68-74, 2011 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-21421030

RESUMEN

Danshen (Salvia miltiorrhiza) contains tanshinones, which inhibit P-glycoprotein (P-gp) and the cytochrome P450 (CYP) system. In the present study, we evaluated the possible pharmacokinetic interactions of Danshen extract with docetaxel and clopidogrel in rats. Docetaxel (5 mg/kg intravenously and 40 mg/kg orally) or clopidogrel (30 mg/kg orally) was administered to rats with or without oral co-administration of Danshen (400 mg/kg). Co-administration of Danshen did not affect the plasma concentration profiles and pharmacokinetic parameters of docetaxel and clopidogrel, whereas cyclosporine A, a P-gp and CYP3A inhibitor, significantly influenced the pharmacokinetics of co-administered docetaxel and clopidogrel. Orally administered Danshen had no substantial effect on the pharmacokinetics of docetaxel and clopidogrel, suggesting the negligible safety concern of Danshen in P-gp- and CYP3A-mediated interactions in vivo.


Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/efectos de los fármacos , Citocromo P-450 CYP3A/efectos de los fármacos , Medicamentos Herbarios Chinos/farmacología , Taxoides/farmacocinética , Ticlopidina/análogos & derivados , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Administración Oral , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos/farmacocinética , Clopidogrel , Ciclosporina/farmacología , Citocromo P-450 CYP3A/metabolismo , Docetaxel , Interacciones de Hierba-Droga , Infusiones Intravenosas , Masculino , Inhibidores de Agregación Plaquetaria/farmacocinética , Ratas , Ratas Sprague-Dawley , Salvia miltiorrhiza/química , Taxoides/administración & dosificación , Ticlopidina/farmacocinética
7.
J Appl Toxicol ; 30(8): 775-8, 2010 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21157986

RESUMEN

It has been reported that urinary excretion of two metabolites of valproic acid (VPA), 4-ene-valproic acid (4-VPA)and 2,4-diene-valproic acid (2,4-VPA), increased exponentially with the administration of high doses of VPA, and this increased formation of toxic metabolites could be related to VPA hepatotoxicity in humans. The aim of this study was to investigate whether the plasma level of 4-VPA and 2,4-VPA in rats corresponds to the urinary data for the same metabolites in humans.After the oral administration of VPA at doses of 20, 100 and 500 mg kg-1 in rats, the AUC0­24 h, 4-VPA/AUC0­24 h, VPA ratios (0.0399,0.0120 and 0.0100 for 20, 100 and 500 mg kg-1, respectively) and AUC0­24 h, 2,4-VPA/AUC0­24 h, VPA ratios (0.00104, 0.00201 and 0.00141, respectively) did not increase with increasing doses of VPA in rats. Thus, the plasma exposure of toxic metabolites normalized by dose remained unchanged (for 2,4-VPA) or even decreased (for 4-VPA) following high-dose VPA administration;this contradicts the findings of previous studies. Our results suggest that toxicity induced by high doses of VPA cannot be explained by a nonlinear increase of toxic metabolites in rats.


Asunto(s)
Hígado/metabolismo , Ácido Valproico/administración & dosificación , Ácido Valproico/farmacocinética , Administración Oral , Animales , Relación Dosis-Respuesta a Droga , Ácidos Grasos Monoinsaturados/sangre , Cromatografía de Gases y Espectrometría de Masas , Humanos , Masculino , Dinámicas no Lineales , Ratas , Ratas Sprague-Dawley , Ácido Valproico/análogos & derivados , Ácido Valproico/sangre
8.
Arch Pharm Res ; 33(12): 2025-31, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21191769

RESUMEN

Hwang-Ryun-Hae-Dok-Tang (HT; a standardized herbal formula consisting of extracts from Coptidis Rhizoma, Scutellariae Radix, Phellodendri Cortex, and Gardeniae Fructus) was reported to modulate a function of multidrug resistance associated protein 2 (Mrp2) in vitro. The aim of this study was to assess the in vivo pharmacokinetic interactions between HT and phenolsulfonphthalein (PSP), a typical model Mrp2 substrate eliminated via bile through Mrp2 in rats. Rats received intravenous PSP (0.8 mg/kg) followed by either a single oral dose of HT (0.42 g/kg) or multiple oral doses of HT (0.42 g/kg for 7 days). The effect of HT treatment was also investigated at a steady-state after intravenous PSP infusion. In contrast to previous in vitro results, in this study, we found that the HT-treated and control groups did not show any significant difference in the plasma PSP concentration and pharmacokinetic parameters, including area under the plasma concentration-time curve (AUC; control: 118 ± 19, single dose: 116 ± 40, and multiple dose: 137 ± 4, in mg/(min·mL)) and biliary clearance (control: 3.15 ± 0.69, single dose: 2.59 ± 1.11, and multiple dose: 2.53 ± 0.65, in mL/(min·kg)). However, cyclosporine A (5 mg/kg, an inhibitor of Mrp2) significantly decreased the AUC and biliary clearance of PSP. The steady-state plasma concentration and biliary clearance of PSP-were also similar between the groups. Taken together, our results suggest that HT may not be affected by Mrp2-mediated herb-drug interaction in vivo.


Asunto(s)
Colorantes/metabolismo , Interacciones de Hierba-Droga , Fenolsulfonftaleína/metabolismo , Extractos Vegetales/metabolismo , Extractos Vegetales/uso terapéutico , Administración Oral , Animales , Área Bajo la Curva , Bilis/efectos de los fármacos , Bilis/metabolismo , Colorantes/farmacocinética , Ciclosporina/metabolismo , Ciclosporina/farmacocinética , Interacciones Farmacológicas , Infusiones Intravenosas , Masculino , Proteína 2 Asociada a Resistencia a Múltiples Medicamentos , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/metabolismo , Fenolsulfonftaleína/farmacocinética , Extractos Vegetales/farmacocinética , Ratas , Ratas Sprague-Dawley
9.
Phytother Res ; 21(12): 1187-92, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17639560

RESUMEN

The individual and combined antistress effects of the fruit of Schizandra chinensis and the radix of Scutellaria baicalensis were evaluated using a mouse acute stress model. Stress consisted of immobilization and electric foot shocks over 5 days. Mice were treated with herbal extracts for 7 days before exposing the animals to stress. Before each stressor presentation, the mice were treated with each herbal extract. Reduced locomotor activity and the percentage of time spent in the open arms of an elevated plus-maze under stress were recovered by treatment with the extract containing equal amounts of S. chinensis and S. baicalensis (CB11) at 200 and 400 mg/kg (p < 0.05). The effects of CB11 were greater than the effects of S. chinensis or S. baicalensis alone. CB11 treatment (100, 200 and 400 mg/kg) significantly reduced serum corticosterone levels (p < 0.05). Spleen size and the serum interleukin-2 level decreases induced by stress were prevented by CB11 (200 mg/kg) (p < 0.05). Taken together, these results suggest that S. chinensis and S. baicalensis in equal amounts could be used to treat stress disorders, in part, by preventing corticosterone and IL-2 level changes and ameliorating stress-related behavior parameters.


Asunto(s)
Fitoterapia , Extractos Vegetales/uso terapéutico , Schisandra , Estrés Fisiológico/tratamiento farmacológico , Estrés Psicológico/tratamiento farmacológico , Animales , Corticosterona/sangre , Interleucina-2/sangre , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Ratones , Ratones Endogámicos ICR , Actividad Motora/efectos de los fármacos , Tamaño de los Órganos/efectos de los fármacos , Extractos Vegetales/farmacología , Restricción Física , Scutellaria baicalensis , Bazo/patología , Estrés Fisiológico/sangre , Estrés Fisiológico/patología , Estrés Psicológico/sangre , Estrés Psicológico/patología
10.
Artículo en Chino | WPRIM | ID: wpr-235247

RESUMEN

<p><b>OBJECTIVE</b>To study on effect of concentration of catalpol and 5-hydroxy methyl-2-furaldehyde (5-HMF) from Rehmanniae Radix at various processing.</p><p><b>METHOD</b>The Rehmanniae Radix was dried and prepared from the steaming process with 10% ethanol, 50% ethanol at 90 degrees C and 100 degrees C each other. And the changes of catalpol and 5-HMF was determinated. The extraction of 5-HMF and catalpol was sonicated in 30% methanol for 2 h. The analysis of 5-HMF and catalpol was conducted by HPLC with reversed-phase C-18 column and detected under UV 284 nm, 204 nm. Elution was carried out at 1.0 mL min(-1) with 3% acetonitrile.</p><p><b>RESULT</b>From this analysis, we found out that the content of catalpol was decreased with the number of processing times, and content of 5-HMF was increased with the number of processing times at various processing. The temperature and concentration of ethanol can effect on content of catalpol and 5-HMF at processing. The Cooked Rehmanniae Radix processed at 100 degrees C, 10% ethanol is best. And the content of 5-HMF processed for more than 7 times was accorded with standard of Korea phamcopoetia.</p><p><b>CONCLUSION</b>Analyze the effect of concentration of catalpol and 5-HMF from Rehmanniae Radix at various processing, and provide the foundation for further study.</p>


Asunto(s)
Cromatografía Líquida de Alta Presión , Etanol , Furaldehído , Glucósidos , Calor , Glucósidos Iridoides , Iridoides , Tubérculos de la Planta , Química , Plantas Medicinales , Química , Rehmannia , Química , Tecnología Farmacéutica , Métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA